NCT02861391 is a NA clinical trial of CO2 AcuPulse Laser in Exposure Laser, sponsored by Rambam Health Care Campus.

Who is sponsoring NCT02861391?

NCT02861391 is sponsored by Rambam Health Care Campus.

What drugs are being tested in NCT02861391?

Interventions in NCT02861391: CO2 AcuPulse Laser, Sham Laser.

What condition does NCT02861391 study?

NCT02861391 studies Exposure Laser.

Is NCT02861391 still recruiting?

NCT02861391 is currently completed. Last updated 17 January 2023.

Last reviewed 2023-01-17 · How we verify

NCT02861391

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Safety and Efficacy of Carbon Dioxide (CO2) Acupulse Laser Treatment on Urinary Stress Incontinence.

Completed NA Last updated 17 January 2023

What this trial tests

NA trial testing CO2 AcuPulse Laser in Exposure Laser in 125 participants. Completed in 30 January 2022.

Timeline

4 October 2019

Primary endpoint
1 November 2021

30 January 2022

Quick facts

Lead sponsor	Rambam Health Care Campus
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	125
Start date	4 October 2019
Primary completion	1 November 2021
Estimated completion	30 January 2022
Sites	1 location across Israel

Drugs / interventions tested

CO2 AcuPulse Laser
Sham Laser

Conditions studied

Exposure Laser — all drugs for Exposure Laser →

Sponsor

Rambam Health Care Campus — full company profile →

Who can join

Adults 18 to 70, female only, with Exposure Laser. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is intended to assess the safety and efficacy of CO2 AcuPulse laser treatment in patients with stress urinary incontinence (SUI). Eligible subjects will either receive 3 laser or sham treatment sessions, 4 weeks apart and 4 Follow Up visits, at 1, 3, 6, and 12 months following the last treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of CO2 AcuPulse Laser

Trials testing the same drug.

NCT02847897 — Evaluation of Safety and Efficacy of Carbon Dioxide (CO2) Acupulse Laser Treatment on Vaginal Elasticity. · NA · completed

Other Rambam Health Care Campus trials

Trials by the same sponsor.

NCT07384013 — Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs · NA · recruiting
NCT06688253 — Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis · Phase 4 · not yet recruiting
NCT06235749 — Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery · NA · recruiting
NCT06622902 — Influence of Flow Rate Change on CO2 Levels During High Flow Nasal Ventilation (HFNV) in Preterm Infants. · NA · recruiting
NCT05922111 — Cervical Ripening Balloon for 12 Hours vs. 1 Hour. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02861391 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rambam Health Care Campus
Last refreshed: 17 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02861391.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing